Abstract
Dopamine agonists are effective in some patients with acromegaly and in this condition treatment is considered to be chronic. We describe two acromegalic patients who responded adequately to the long-acting dopamine agonist cabergoline, but surprisingly maintained normal GH and IGF-I levels once therapy was discontinued after 42 and 76 months because of possibly related side effects. A 32-year-old woman with mild acromegaly (IGF-I: 423 μg/l, GH after OGTT: 2.5 μg/l, adenoma 4 mm) was treated with cabergoline as primary therapy and reached safe GH levels (2 μg/l or less) and normal IGF-I levels with 3.5 mg cabergoline weekly. After 42 months of therapy the patient experienced a progressive decrease of libido, which she attributed to the intake of cabergoline. After stopping medication, serum levels of GH and IGF-I remained normal during the following 2.5 years. A 53-year-old man with moderate acromegaly (serum IGF-I: 547 μg/l, GH after OGTT: 5.9 μg/l, adenoma 7 mm) preferred cabergoline as primary therapy. Serum GH levels below 2 μg/l and normal levels of IGF-I were obtained with 3.5 mg cabergoline weekly. When the patient experienced severe stomach pains after 76 months of treatment, cabergoline was held responsible and discontinued. Serum GH and IGF-I did not increase again and stayed at the same level during a follow-up of 5.5 years. These two cases demonstrate that acromegalic patients with a good response to cabergoline may occasionally remain in remission after stopping therapy. This phenomenon has previously only been described in patients with a prolactinoma.
References
Bates AS, Van’t Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86:293–299
Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573
Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10:611–619
Monson JP (2006) Is there still a role for radiotherapy in acromegaly? Neuroendocrinology 83:269–273
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374–378
Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J (1997) Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab 82:23–28
Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577–584
Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151:317–324
Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177
Jaffe CA, Barkan AL (1992) Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 121:713–735
Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518–523
Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2:23–32
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med 331:904–909
Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin-secreting macroadenoma with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522
Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P,Dubini A (1988) Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 29:467–476
Jackson SNJ, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46:745–749
Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209–215
Selvarajah D, Webster J, Ross R, Newell-Price J (2005) Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152:569–574
Gatta B, Hau DH, Catargi B, Roger P, Tabarin A (2005) Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 63:477–478
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033
Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537–546
Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subject with microprolactinomas. Clin Endocrinol (Oxf) 63:26–31
Nishioka H, Haraoka J, Miki T (2005) Spontaneous remission of functioning pituitary adenomas without hypopituitarism following infarctive apoplexy: two case reports. Endocr J 52:117–123
Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumoto S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23:395–398
Alhajje A, Lambert M, Crabbe J (1985) Pituitary apoplexy in an acromegalic patient during bromocriptine therapy. Case report. J Neurosurg 63:288–292
Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol (Berl) 111:46–52
Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R (2000) Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 11:341–352
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verhelst, J.A., Abrams, P.J. & Abs, R. Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11, 103–107 (2008). https://doi.org/10.1007/s11102-007-0041-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-007-0041-y